Hana Pharm Co., Ltd.
KRX:293480.KS
11310 (KRW) • At close November 1, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) KRW.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 224,456.851 | 210,844.992 | 196,406.571 | 177,305.504 | 166,346.999 | 152,832.774 | 139,331.266 | 124,534.999 | 108,942.199 |
| Cost of Revenue
| 83,600.955 | 79,605.02 | 65,588.671 | 63,282.627 | 56,149.783 | 50,925.879 | 44,953.699 | 40,622.785 | 38,546.981 |
| Gross Profit
| 140,855.896 | 131,239.972 | 130,817.9 | 114,022.877 | 110,197.216 | 101,906.895 | 94,377.566 | 83,912.213 | 70,395.218 |
| Gross Profit Ratio
| 0.628 | 0.622 | 0.666 | 0.643 | 0.662 | 0.667 | 0.677 | 0.674 | 0.646 |
| Reseach & Development Expenses
| 13,233.133 | 4,748.276 | 3,489.306 | 3,241.968 | 2,561.84 | 2,190.562 | 2,214.49 | 3,423.579 | 3,184.634 |
| General & Administrative Expenses
| 29,316.695 | 28,173.471 | 24,357.595 | 20,502.142 | 19,109.122 | 17,677.216 | 16,203.584 | 14,855.79 | 0 |
| Selling & Marketing Expenses
| 25,937.29 | 19,982.259 | 16,660.878 | 6,147.003 | 6,556.428 | 6,430.646 | 5,977.471 | 5,711.86 | 0 |
| SG&A
| 100,770.942 | 48,155.73 | 41,018.473 | 26,649.145 | 25,665.55 | 24,107.862 | 22,181.055 | 20,567.65 | 50,624.941 |
| Other Expenses
| -721.221 | 47,165.211 | 50,300.061 | 52,456.676 | 48,403.247 | 30.706 | -146.241 | -173.602 | -1,144.504 |
| Operating Expenses
| 114,725.296 | 100,069.217 | 94,807.84 | 82,347.789 | 76,630.637 | 68,343.869 | 62,447.924 | 60,241.535 | 54,954.079 |
| Operating Income
| 26,130.6 | 31,170.755 | 36,010.06 | 31,675.088 | 33,566.579 | 33,563.026 | 31,929.643 | 23,670.679 | 15,441.139 |
| Operating Income Ratio
| 0.116 | 0.148 | 0.183 | 0.179 | 0.202 | 0.22 | 0.229 | 0.19 | 0.142 |
| Total Other Income Expenses Net
| 1,776.357 | -452.404 | -163.208 | -3,179.715 | 1,295 | -1,231.166 | -968.801 | -1,720.249 | -3,310.359 |
| Income Before Tax
| 27,906.956 | 30,718.351 | 35,846.852 | 28,495.373 | 34,861.579 | 32,331.859 | 30,960.841 | 21,950.429 | 12,130.78 |
| Income Before Tax Ratio
| 0.124 | 0.146 | 0.183 | 0.161 | 0.21 | 0.212 | 0.222 | 0.176 | 0.111 |
| Income Tax Expense
| 5,574.186 | 6,411.172 | 7,833.016 | 13,602.508 | 6,557.855 | 6,162.785 | 6,658.355 | 4,519.581 | 7,219.424 |
| Net Income
| 22,332.77 | 24,307.179 | 28,013.836 | 14,892.865 | 28,303.725 | 26,169.074 | 24,304.638 | 17,430.848 | 4,911.356 |
| Net Income Ratio
| 0.099 | 0.115 | 0.143 | 0.084 | 0.17 | 0.171 | 0.174 | 0.14 | 0.045 |
| EPS
| 1,290.95 | 1,405.08 | 1,679.05 | 860.74 | 1,616.79 | 1,794.94 | 2,039.09 | 2,043.64 | 275.61 |
| EPS Diluted
| 1,290.95 | 1,405.08 | 1,679.05 | 860.74 | 1,616.79 | 1,794.5 | 2,039.09 | 2,043.64 | 275.61 |
| EBITDA
| 33,710.449 | 38,858.104 | 41,719.704 | 33,262.604 | 39,702.275 | 37,505.045 | 35,470.087 | 27,230.278 | 19,342.176 |
| EBITDA Ratio
| 0.15 | 0.184 | 0.212 | 0.188 | 0.239 | 0.245 | 0.255 | 0.219 | 0.178 |